|The following article features coverage from the American Society of Clinical Oncology 2020 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Among patients with HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) shows promising efficacy, according to research presented at the ASCO20 Virtual Scientific Program.
T-DXd, which is composed in part of an anti-HER2 antibody, showed promising effectiveness in a previous phase 1 trial in patients with HER2-mutated NSCLC. In DESTINY-Lung01 (ClinicalTrials.gov identifier: NCT03505710), an ongoing phase 2 trial of T-DXd, researchers are evaluating the drug’s safety and efficacy among patients with non-squamous NSCLC which either overexpresses HER2 or contains a HER2-activating mutation. For this presentation, the authors highlighted the interim results from cohort 2 — patients with a HER2 mutation — of DESTINY-Lung01.
All included patients have unresectable or metastatic NSCLC, which has either relapsed or is refractory to standard treatment, and have received no prior HER2 targeted therapy, except for pan-HER tyrosine kinase inhibitors. The study’s primary outcome is overall response rate (ORR).
Overall, 84 patients have been enrolled, with 42 in cohort 1 (HER2 overexpression) and 42 in cohort 2. In cohort 2, the median age was 63 years, 64.3% of patients were female, and 45.2% had central nervous system metastases.
At the data cut-off point in November 2019, 45.2% (19) of patients in cohort 2 had remained on study treatment.
The median follow-up was 8 months. Twenty-six (61.9%) patients had an ORR as confirmed by independent central review. Among these, 1 (2.4%) was a complete response and 25 (59.5%) were partial responses. Twelve (28.6%) patients had stable disease, 2 (4.8%) had progressive disease, and 2 (4.8%) did not have evaluable data.
The duration of response was not reached (95% CI, 5.3-not reached), and the median progression-free survival was 14 months (95% CI, 6.4-14).
Overall, the median treatment duration was 7.76 months. All patients had a treatment-related adverse event (AE), with 27 (64.3%) having a grade 3 or worse AE. Serious drug-related AEs occurred in 7 (16.7%) patients.
The authors noted that interstitial lung disease was an AE of special interest, which occurred in 5 patients, but was not associated with any deaths.
Five patient deaths occurred in conjunction with a treatment-related AE, but the investigators did not determine these to be related to the drug.
Read more of Cancer Therapy Advisor‘s coverage of the ASCO 2021 meeting by visiting the conference page.
Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. Presented at: ASCO20 Virtual Scientific Program. J Clin Oncol. 2020;38(suppl):abstr 9504.